Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ad26 EBOV vaccine - Crucell/NIH

Next Previous
Drug Profile

Ad26 EBOV vaccine - Crucell/NIH

Alternative Names: Ad26 EBOV vaccine - NIH/Crucell; Ad26-ZEBOV - Crucell/NIH; Ad26-ZEBOV - NIH/Crucell; Ad26.ZEBOV; Ad26.ZEBOV - NIH/Crucell; Ebola virus vaccine - Crucell/NIH; Ebola virus vaccine - NIH/Crucell; rHAd26; VAC-52150; Zabdeno

Latest Information Update: 18 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crucell; National Institutes of Health (USA)
  • Developer Bavarian Nordic; Crucell; Janssen; London School of Hygiene & Tropical Medicine; National Institute of Allergy and Infectious Diseases
  • Class Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Ebola virus infections

Most Recent Events

  • 13 Dec 2023 Janssen terminates a phase III trial for Ebola virus infections (In adolescents, In children, In the elderly, Prevention, In adults, In infants, In neonates) in USA, Burkina Faso, France, Kenya, Tanzania, Uganda, and the UK due to the pandemic with only one participant in follow up, as the impact on the safety was determined to be negligible (NCT02661464)
  • 02 Mar 2023 Janssen completes phase-III clinical trial in Ebola virus infections (Prevention, In adults, In the elderly) in Rwanda (IM) (NCT04556526)
  • 02 Dec 2022 No development reported - Phase-II for Ebola virus infections (In adolescents, In children, In the elderly, Prevention, In adults) in Uganda (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top